Alterations in the global proteome and phosphoproteome in third-generation EGFR TKI resistance reveal drug targets to circumvent resistance

Lung cancer is the leading cause of cancer mortality worldwide. The treatment of lung cancer patients harboring mutant EGFR with orally administered EGFR tyrosine kinase inhibitors (TKIs) has been a paradigm shift. Osimertinib and rociletinib are third-generation irreversible EGFR TKIs targeting the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Zhang, Xu, Maity, Tapan K., Ross, Karen E., Qi, Yue, Cultraro, Constance M., Bahta, Meriam, Pitts, Stephanie, Keswani, Meghana, Gao, Shaojian, Nguyen, Khoa Dang P., Cowart, Julie, Kirkali, Fatos, Wu, Cathy, Guha, Udayan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8182571/
https://ncbi.nlm.nih.gov/pubmed/33727228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2435
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi